Differential associations of beta‐blockers with hemorrhagic events for chronic heart failure patients on warfarin

Beta‐blockers have many different physiologic effects that could potentially influence the risk of hemorrhagic events in chronic heart failure patients (CHF) on warfarin. We examined how different beta‐blockers vary in their associated risk of a hemorrhagic event.

[1]  G. Tucker,et al.  The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin. , 1984, British journal of clinical pharmacology.

[2]  K. Winther.  The Effect of &bgr;‐Blockade on Platelet Function and Fibrinolytic Activity , 1987, Journal of cardiovascular pharmacology.

[3]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[4]  D. Petitti,et al.  Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. , 1989, Journal of clinical epidemiology.

[5]  L Goldman,et al.  Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. , 1989, The American journal of medicine.

[6]  T. Poynard,et al.  Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. , 1991, The New England journal of medicine.

[7]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[8]  J. Csöllei,et al.  Comparison of the potency of five potential beta-adrenoceptor blocking drugs and eight calcium channel blockers to inhibit platelet aggregation and to perturb liposomal membranes prepared from platelet lipids. , 1992, Physiological research.

[9]  R. Beyth,et al.  Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. , 1993, The American journal of medicine.

[10]  J. Cohn,et al.  The management of chronic heart failure. , 1996, The New England journal of medicine.

[11]  X. Cussó,et al.  Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. , 1996, The New England journal of medicine.

[12]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[13]  K. Fox,et al.  Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. , 1997, Circulation.

[14]  A. Chak,et al.  The effectiveness of early endoscopy for upper gastrointestinal hemorrhage: a community-based analysis. , 1998, Medical care.

[15]  Kashner Tm.  Agreement between administrative files and written medical records: a case of the Department of Veterans Affairs. , 1998 .

[16]  R. Korbut,et al.  Thrombolytic activity of beta-adrenolytic drug, sotalol. , 1998, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[17]  T. Baglin,et al.  Analysis of risk factors for over‐anticoagulation in patients receiving long‐term warfarin , 1998, British journal of haematology.

[18]  Heather L. Heiman,et al.  Acetaminophen and other risk factors for excessive warfarin anticoagulation , 1998 .

[19]  P. Hayes,et al.  Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. , 1999, Journal of hepatology.

[20]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[21]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[22]  R. Beyth,et al.  Major bleeding after hospitalization for deep-venous thrombosis. , 1999, The American journal of medicine.

[23]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[24]  G. Lip,et al.  Abnormalities of Hemorheological, Endothelial, and Platelet Function in Patients With Chronic Heart Failure in Sinus Rhythm: Effects of Angiotensin-Converting Enzyme Inhibitor and &bgr;-Blocker Therapy , 2001, Circulation.

[25]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[26]  V. Mor,et al.  Effect of Antiplatelet and Anticoagulant Agents on Risk of Hospitalization for Bleeding Among a Population of Elderly Nursing Home Stroke Survivors , 2001, Stroke.

[27]  E. Ellerbeck,et al.  The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation , 2002, Pharmacoepidemiology and drug safety.

[28]  Mary K Goldstein,et al.  Accuracy of computerized outpatient diagnoses in a Veterans Affairs general medicine clinic. , 2002, The American journal of managed care.

[29]  A. LaCroix,et al.  Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study. , 2002, Journal of clinical epidemiology.

[30]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[31]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[32]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[33]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[34]  David B. Matchar,et al.  Relationship Between Test Frequency and Outcomes of Anticoagulation: A Literature Review and Commentary with Implications for the Design of Randomized Trials of Patient Self-Management , 2000, Journal of Thrombosis and Thrombolysis.

[35]  D. Berlowitz,et al.  Identifying Hypertension-Related Comorbidities From Administrative Data: What's the Optimal Approach? , 2004, American journal of medical quality : the official journal of the American College of Medical Quality.

[36]  Effects of three beta-blockers with different pharmacodynamic properties on platelet aggregation and platelet and plasma cyclic AMP , 2004, European Journal of Clinical Pharmacology.

[37]  E. Eldrup,et al.  Differential effects of timolol and metoprolol on platelet function at rest and during exercise , 2004, European Journal of Clinical Pharmacology.